A team of CNIO researchers, in collaboration with the Spanish Oncology Genitourinary Group (SOGUG) and the University Hospitals Leuven (Belgium), has discovered various potential biomarkers predictive of tyrosine kinase inhibitors ...
Jul 7, 2016
0
0
A University of Colorado Cancer Center study presented at the American Association for Cancer Research Annual Meeting 2016 pinpoints ways that cancer cells evolve to resist the drug LOXO-101, a kinase inhibitor of the TRK-fusion ...
Apr 18, 2016
0
4
With the expiration in January of the patent on Gleevec, the drug that 15 years ago changed chronic myeloid leukemia (CML) from a death sentence to a treatable illness, insurance companies and patients have the opportunity ...
Mar 15, 2016
0
2
(HealthDay)—Cola intake leads to a clinically relevant and statistically significant increase in the bioavailability of erlotinib during esomeprazole treatment, according to a study published online Feb. 8 in the Journal ...
Feb 10, 2016
0
1
The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current ...
Feb 5, 2016
0
155
Due to their rapid metastatic spread, pancreatic tumors are among the most aggressive types of cancer. Only three to five percent of patients have a survival rate of five years. A team of KIT researchers has now established ...
Nov 10, 2015
0
4
Targeted treatments for cancer have been extending and saving lives for more than 15 years—precision medicine isn't a new idea in oncology. Now drugs pioneered on select, specific cancers are, one by one, finding new applications.
Sep 4, 2015
0
292
Targeted therapies attack a cancer's genetic sensitivities. However, it can be difficult to discover the genetics driving a patient's cancer, and the effects of drugs designed to target a genetic abnormality often go beyond ...
Jul 28, 2015
0
23
Manchester scientists have genetically mapped the cancer of a leukaemia patient whose disease was resistant to treatment in order to identify a method of personalising therapy for individuals.
Jul 14, 2015
0
13
Manchester scientists have a developed a new method to monitor the effect of anti-cancer drugs on very rare leukaemia stem cells. The approach potentially allows doctors to screen patients and personalise their treatment.
Feb 27, 2015
0
34
